This report on the menopausal hot flashes market studies the current and future prospects of the treatment across the globe. Hot flashes are common symptoms experience by women in menopause transition. Hot flashes are defined as ephemeral, recurring periods of heat sensation and redness, often associated with sweat and are experienced by about 75% of women in the U.S and Europe at some point before or during the menopause period. These tend to decrease in severity and frequency over a few months to a few years, but sometimes persist into old age.
The menopausal hot flashes market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global menopausal hot flashes drugs market with respect to the segments based on the type of therapy, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global menopausal hot flashes market.
Based on therapy type, the menopausal hot flashes market has been segmented into two major categories: hormonal and non-hormonal treatment. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.
Geographically, the global menopausal drugs market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, France, Rest of Europe), Asia Pacific (Japan, Australia, India, China, Rest of Asia Pacific), and Rest of the World (Latin America, Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.
The report also profiles major players in the global menopausal hot flashes market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Allergan plc, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Merck & Co. Inc., Novartis International AG, Novo Nordisk, Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.
The global menopausal hot flashes market is segmented as follows:
Global Menopausal Hot Flashes Market, by Therapy Type
- Combination Therapy
Global Menopausal Hot Flashes Market, Pipeline Analysis
- Phase I and II Drugs
- Phase III Drugs
Global Menopausal Hot Flashes Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Rest of the World
- Latin America
- Middle East and Africa
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
2. Executive Summary
2.1. Menopausal Hot Flashes Market Snapshot
2.2. Global Menopausal Hot Flashes Market Share, by Geography, 2014 & 2023 (Value %)
2.3. Global Menopausal Hot Flashes Market Revenue, by Geography, 2014 (US$ Mn)
2.4. Global Menopausal Hot Flashes Market, by Therapy, 2014 (US$ Mn)
3. Menopausal Hot Flashes Market - Industry Analysis
3.2. Market Dynamics
126.96.36.199. Rise in menopausal vasomotor symptoms across the globe
188.8.131.52. Approval of new treatment options
184.108.40.206. Growing women health awareness
220.127.116.11. Risk of breast cancer with HRT treatment
18.104.22.168. Growing demand for alternative therapies
22.214.171.124. Emerging economies to offer sustained growth opportunities
3.3. Market Attractiveness Analysis, by Geography, 2014
3.4. Competitive Landscape, Market Share Analysis, by Key Players, 2014 (Value %)
4. Market Segmentation – By Therapy
4.2. Global Menopausal Hot Flashes Revenue, by Therapy, 2013–2023 (US$ Mn)
4.3. Global Menopausal Hot Flashes Market Revenue, by Product, 2013–2023, (US$ Mn)
4.4. Global Hormonal Therapy Market Revenue, by Product, 2013–2023, (US$ Mn)
4.4.1. Global Estrogen Market Revenue, 2013–2023, (US$ Mn)
126.96.36.199. Global Premarin Flashes Market Revenue, 2013–2023, (US$ Mn)
188.8.131.52. Global Vivelle-Dot Market Revenue, 2013–2023, (US$ Mn)
4.4.2. Global Progestin Market Revenue, 2013–2023, (US$ Mn)
184.108.40.206. Global Prometrium Market Revenue, 2013–2023, (US$ Mn)
4.4.3. Global Combination Therapy Market Revenue, 2013–2023, (US$ Mn)
220.127.116.11. Global Duavee Market Revenue, 2013–2023, (US$ Mn)
18.104.22.168. Global Prempro Market Revenue, 2013–2023, (US$ Mn)
4.5. Global Non-hormonal Market Revenue, 2013–2023, (US$ Mn)
4.5.1. Global Brisdelle Market Revenue, 2013–2023, (US$ Mn)
5. Pipeline Analysis
5.1. Phase I and II Drugs, Tabular Representation
5.2. Menopausal Hot Flashes Phase III Drugs Market Revenue, 2017 - 2023 (USD Million)
6. Market Segmentation – By Geography
6.1. Global Menopausal Hot Flashes Market Revenue, by Geography, 2013–2023
6.1.1. North America Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
6.1.2. Europe Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
6.1.3. Asia Pacific Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
6.1.4. Rest of the World Menopausal Hot Flashes Market Revenue, by Country, 2013–2023 (US$ Mn)
8. Company Profiles
8.1. Allergan plc
8.2. Bayer AG
8.3. Hisamitsu Pharmaceutical Co., Inc.
8.4. Merck & Co., Inc.
8.5. Npvartis International AG
8.6. Novo Nordisk
8.7. Pfizer, Inc.
8.8. Teva Pharmaceutical Industries Ltd.
Hot flashes are characteristic symptoms of menopausal women, though could result from other medical conditions too. The symptoms include sudden sensation of intense warmth spreading over body lasting for several minutes leading to sweating, red flush, and palpitations. The severity of these symptoms can vary from woman to woman. Other causes of hot flashes include breast and prostate cancer treatments. Hormone replacement therapy (HRT) is the most effective treatment for menopausal hot flashes. However, long term HRT has an increased risk of breast cancer and risk associated with increasing age such as stroke, blood clots, and other health related problems. Other therapies include intake of vitamin E supplements and anti-depressants along with various complementary therapies. In the U.S. and other developed countries approximately 70% of menopausal women experience hot flashes that can last for several years. According to a publication by Harvard Medical School, on average, hot flashes can last for about 7 years to 11 years.
The menopausal hot flashes market has been segmented on the basis of product, and geography. The product segment has been further segmented into hormonal (estrogen, progestin and combination) and non-hormonal products. Estrogen accounted for the largest share of the global menopausal hot flashes market in terms of revenue as well as prescription volume. Estrogen position in hot flashes treatment market is unchallenged as none of the other available drugs is as effective as estrogen. Some of the recent studies show that non-estrogen drugs may have up to 70% of the effectiveness of estrogen therapy when treating hot flashes. The hormonal hot flashes market has experienced sluggish growth over the past decade. However, it is expected to witness a substantial change between 2015 and 2023. Several market-leading therapies, including Vivelle-Dot (estrogen) by Novartis and Premarin (conjugated estrogens) by Pfizer have lost patent and few more drugs would go off-patent in the next few years. Furthermore, a number of vaginal patches, oral estrogens, and vaginal creams would lose exclusivity, leading to abundance of cheaper generic options in the market. However, with the elevated risk of cancer (womb) in certain group of population is the major restrain for this therapy, especially in the developed world. Moreover, the non-hormonal segment is likely to expand at the highest rate from 2015 to 2023, owing to it being considered as a best option to avoid the increased risk of cancer in certain high risk populations. Non-hormonal therapy includes antidepressants and other prescription drugs that offer relief for some women. Brisdelle is the only non-hormonal medication approved by the FDA for treating hot flashes. Nonetheless, it is expensive as compared to generic formulations, rendering it a limiting factor for its future market penetration.
On the basis of geography, the menopausal hot flashes market has segmented into: North America, Europe, Asia Pacific, Latin America, the Middle East and North Africa (MENA), and Rest of the World (RoW). North America was the largest regional market for menopausal hot flashes treatment, followed by Europe in 2014. The dominance of these two regions is attributed to the presence of large population of menopausal women experiencing hot flashes than any other part of the world. Furthermore, increasing demand for non-hormonal drugs is likely to fuel market growth in this region from 2015 to 2023. Asia Pacific is anticipated to witness the fastest growth rate during the forecast period. In addition to large population pool, rising disposable income, rapid urbanization, and increase in women’s health expenditure across the region support market growth in the region. The menopausal hot flashes market in Rest of the World offers large opportunities and is projected to expand at a decent rate in the next few years. Driving factors for the region include improving health care infrastructure and growing menopause women in this region. According to a review article published in 2014, the number of women approaching menopause in Brazil is increasing. Of the 30 million women in Brazil, around 32% are aged between 35 and 65 years. This has created an ample of opportunities for both domestic and international companies.
The menopausal hot flashes market is highly fragmented due to the presence of large number of small and medium generic manufacturing companies across the world. Top ten manufacturers accounted for around 44.5% of the market in 2014. Key players operating in the market include Allergan plc, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk Corporation, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.